Orthofix Medical (OFIX) to Release Quarterly Earnings on Tuesday

Key Points

• Orthofix Medical is set to announce its Q2 2025 earnings results on August 5th, with expectations of earnings at $0.04 per share and revenue of $196.89 million.
• CEO Massimo Calafiore recently purchased 10,000 shares at an average price of $12.54, increasing his stake in the company to approximately $2.94 million.
• Analysts have mixed ratings for Orthofix Medical, with an average rating of "Moderate Buy" and a notable price target of $21.50.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $196.89 million for the quarter.

Orthofix Medical Trading Down 2.4%

OFIX traded down $0.27 on Friday, reaching $10.77. 332,763 shares of the company's stock were exchanged, compared to its average volume of 270,998. The company has a market cap of $421.97 million, a price-to-earnings ratio of -2.92 and a beta of 0.82. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $20.73. The company's 50 day moving average is $11.03 and its 200-day moving average is $14.13. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.71.

Insider Activity at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the transaction, the insider directly owned 46,322 shares of the company's stock, valued at approximately $486,844.22. This trade represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Massimo Calafiore purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average price of $12.54 per share, with a total value of $125,400.00. Following the transaction, the chief executive officer directly owned 234,603 shares in the company, valued at $2,941,921.62. This trade represents a 4.45% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 113,500 shares of company stock valued at $1,394,858. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Orthofix Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Orthofix Medical in the 1st quarter valued at approximately $1,076,000. Strs Ohio bought a new position in Orthofix Medical in the 1st quarter valued at $150,000. AQR Capital Management LLC raised its position in shares of Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock worth $333,000 after acquiring an additional 8,241 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock valued at $335,000 after purchasing an additional 1,213 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Barrington Research upgraded Orthofix Medical to a "strong-buy" rating and set a $16.00 target price for the company in a research note on Monday, June 23rd. Wall Street Zen cut Orthofix Medical from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. Finally, JMP Securities reiterated a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.50.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.